About Elevation oncology
Elevation Oncology: Elevating Precision Medicine to the Forefront of Cancer Treatment
Cancer is a complex disease that affects millions of people worldwide. It is a leading cause of death, and despite advances in medical research, there is still much to be done in terms of finding effective treatments. Elevation Oncology is a company that aims to change this by elevating precision medicine to the forefront of every cancer treatment journey.
At Elevation Oncology, they believe that every patient deserves personalized care based on their unique genetic makeup. They make drugs that make genomic tests actionable, which means they develop targeted therapies for patients with specific genetic mutations. This approach allows them to create more effective treatments with fewer side effects.
Elevation Oncology was founded in 2018 by Shawn M. Leland and Dr. Razelle Kurzrock, two experts in precision medicine and oncology respectively. Their goal was to create a company that could bridge the gap between genomic testing and drug development.
The company's flagship drug candidate is called "EO1001," which targets patients with NRG1 fusions - a rare but aggressive form of cancer found in various tumor types such as lung cancer, pancreatic cancer, breast cancer etc.. EO1001 has shown promising results in preclinical studies and has received FDA orphan drug designation for its potential use against NRG1 fusion-positive cancers.
Elevation Oncology's approach to drug development involves collaboration with leading academic institutions such as MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center. By working closely with these institutions, they can leverage their expertise in genomics and oncology research while also gaining access to patient populations for clinical trials.
In addition to developing targeted therapies for specific genetic mutations, Elevation Oncology also focuses on biomarker-driven clinical trials - another aspect of precision medicine where patients are selected based on specific biomarkers rather than broad disease categories like "lung cancer" or "breast cancer." This approach allows for more efficient clinical trials and better patient outcomes.
Elevation Oncology's commitment to precision medicine is reflected in their team of experts, which includes scientists, clinicians, and industry veterans with decades of experience in drug development. They are dedicated to advancing the field of oncology by developing innovative therapies that can improve patient outcomes and quality of life.
In conclusion, Elevation Oncology is a company that is elevating precision medicine to the forefront of cancer treatment. Their focus on targeted therapies for specific genetic mutations and biomarker-driven clinical trials has the potential to revolutionize how we treat cancer. With their flagship drug candidate EO1001 showing promising results in preclinical studies, they are well on their way to achieving this goal. As they continue to collaborate with leading academic institutions and attract top talent in the field, Elevation Oncology is poised to make a significant impact on oncology research and patient care.